ABSTRACT The globular head of the trimeric influenza hemagglutinin (HA) contains the receptor-binding domain (RBD) and is the target of potently neutralizing human monoclonal antibodies (mAbs) with high in vivo activity. In general, these mAbs are induced easily by vaccination, but only infrequently display cross-neutralizing activity against antigenic drift variants or even against HA molecules from viruses of heterologous subtypes. Recently, the atomic resolution structures of several such antibodies in complex with HA have been determined by X-ray crystallography. Not surprisingly, cross-reactive globular head antibodies target, at least partially, the conserved RBD. The cross-reactive potential of such mAbs is limited by contacts of hypervariable HA residues outside the conserved RBD. The RBD of H2 HA seems especially immunogenic. Increasing the immunogenicity of the RBD of other HA subtypes may be a step toward a universal influenza vaccine. The germ line-encoded Phe54 residue of the CDR-H2 of the V H 1-69 germ line sequence appears to be ideally suited not only to reach into a conserved, hydrophobic pocket on the HA stem, but also to reach into the conserved, hydrophobic pocket that is the RBD. We have cloned antibodies from different individuals that are encoded by the V H 1-69 germ line gene segment that contact the universally conserved Trp153 on the bottom of the RBD. These antibodies serve as further evidence of antibody genetic sequence convergence across individuals.
INFLUENZA HEMAGGLUTININ IS A TRIMERIC GLYCOPROTEIN OF THREE IDENTICAL SUBUNITS AND THE MAJOR PROTECTIVE ANTIGEN OF THE VIRUS
Influenza hemagglutinin (HA) is the major glycoprotein on the surface of influenza virions. It mediates receptor binding and fusion. The surface glycoprotein neuraminidase (NA) is a receptor-destroying enzyme. Even though humoral immunity to NA and other proteins and cellular immunity to several viral proteins contribute to protection against influenza infection, neutralizing antibodies directed against influenza HA are sufficient to protect against disease. The H3 HA crystal structure was solved in 1981 at 3-Å resolution (1) . Since then, the crystal structures of HA molecules from H2, H5, H7, and several different H1 strains including the pandemic 1918 H1 and the pandemic 2009 H1 (2) have been determined. In brief, HA is a trimeric type I membrane glycoprotein made of three identical subunits (Fig. 1) . Each subunit is synthesized as an HA0 precursor and cleaved proteolytically into an HA1 subunit that composes the membrane-distal globular head and part of the membrane-proximal stem region, and an HA2 subunit that only contributes to the stem region (Fig. 1) .
The receptor-binding domain (RBD) of HA forms a conserved pocket on the globular head (Fig. 1) . Antibodies that target the RBD or adjacent hypervariable loops can inhibit hemagglutination of red blood cells in vitro and binding to sialic acid of respiratory epithelial cells (Table 1 ). In contrast, neutralizing antibodies against the HA stem domain can prevent the pH-induced conformational change that occurs in the endosome after binding to and internalization into the host cell or by interfering with the maturation of HA0 to HA1 and HA2 (3, 4) . After the discovery of the murine HA stem-specific monoclonal antibody (mAb) C179 in 1993 (5) that neutralizes H1, H2, and H5 viruses, several groups have reported that humans can generate mAbs against the influenza HA stem as well, many of which are encoded by the V H 1-69 germ line gene that specifies amino acids that seem ideally configured to reach into a hydrophobic pocket on the stem. The frequency of antibodies to the conserved HA stem region may have been increased in infected individuals after the 2009 H1N1 pandemic (6) . This observation may represent a special case of original antigenic sin (7, 8, 9, 10) , much talked about in the influenza field, although one might argue that, in fact, the boosting of antibodies to conserved epitopes is consistent with the conventional understanding of B-cell memory. The original antigenic sin theory suggests that, after repeated antigenic exposure, the antibody response is biased toward epitopes that were present in the original antigenic exposure and against new related antigens that cause subsequent exposures. Some people have hypothesized that such crossreactive stem antibodies lead to prepandemic influenza strains becoming extinct (11) . However, the frequency of antibodies to conserved epitopes on the globular head of HA also appeared to be increased after the 2009 H1N1 pandemic (12, 13, 14, 15) . Such antibodies also could have limited the circulation of prepandemic H1N1 strains. We have cloned mAbs to the H2N2 virus that circulated in humans from 1957 until 1968 from the peripheral blood of healthy donors of an appropriate age to have had exposure to H2 viruses (16) . These mAbs were directed against highly conserved epitopes on the head of HA (16, 17) . If such antibodies were present on a population level, they probably would limit the circulation of H2 viruses in the human population even more so than stem antibodies because of their vastly superior potency. In general, HA globular head antibodies seem to be more frequent than stem antibodies probably because their epitope is more readily accessible on the surface of the virus and can be targeted by a wide diversity of antibodies encoded by a broad variety of antibody germ line genes (Table 1) . A lot of interest has been devoted recently toward presenting this conserved HA stem region as part of a universal vaccine against influenza because of the exciting isolation of cross-neutralizing antibodies directed against the conserved HA stem region (18). With the recent discovery of several cross-neutralizing HA globular head antibodies, the HA globular head also appears as an attractive target for vaccine design. This finding seems particularly important because the access of antibodies to the globular head is not hindered by steric constraints and because the most potent HA globular head antibodies neutralize more strongly than HA stem antibodies. Furthermore, the cocrystal structures of HA globular head antibodies in complex with HA may further serve as starting points for the design of inhibitors against the RBD. Therefore, it seems timely to review the literature on HA globular head antibodies.
THE FIRST ANTIGENIC MAPPING
The first mouse monoclonal antibodies against influenza A HA were generated by hybridoma technology in the early 1980s. By testing these mAbs in competition assays and/or through the selection and sequencing of escape mutants in embryonated egg cells, an antigenic mapping of the HA globular head could be performed for H1, H2, and H3 viruses. For the H1 antibodies, antigenic sites designated Sa, Sb, Ca 1 , Ca 2 , and Cb were proposed-the "S" standing for strain-specific and the "C" for crossreactive (19) . Somewhat ironically, the preservation of the supposedly strain-specific Sa antigenic site of the 1918 H1N1 HA in the pandemic 2009 virus was a major reason for antibody cross-reactivity between those two strains (2, 20, 21) . Antibodies that recognized multiple antigenic sites of the globular head of HA had already been identified in the 1980s (19) . More recent X-ray cocrystallization experiments have shown subsequently that antibodies, such as 2D1 that is oriented above the center of the Sa site with its large surface area, recognize residues outside the Sa epitope and even residues within neighboring antigenic sites (2) . Human antibodies that bind a single, discrete antigenic loop of a conventionally defined site on the HA head domain are probably the exception rather than the rule. The antigenic mapping of murine antibodies may not translate directly to that of human antibodies, since the antibody repertoires of different species use entirely different germ line genes. Still, it can helpful to use the antigenic mapping terms in some instances to orient influenza scientists to features on the HA globular head. One could easily use terms such as "190-helix" instead of "Sb antigenic site," but even epitopes such as the Sb antigenic site that was supposed to be a linear epitope (22) seem like a rather complex epitope of multiple loops (23) . Even antibodies that target the conserved receptor-binding sites often touch this 190-helix or Sb site (Table 2) .
For H3, antigenic sites designated A to D were established (24) . Around the year 2000, three cocrystal structures of mouse H3 globular head antibodies were solved in complex with their HA (25, 26, 27, 28) in work reviewed in detail by Knossow and Skehel (29) . The antigenic structure of each HA subtype is slightly different, and one should exercise caution when using the antigenic mapping from the HA of one subtype to describe the topography of the HA from an entirely different subtype. A case in point is the H2 HA. In the initial antigenic mapping, the authors were unable to establish discrete antigenic sites on H2 HA, since most epitopes overlapped (30) . Also, about half of the antibodies cloned were influenced by receptor specificity (30) . We now know that receptor specificity of H2 viruses is mediated by residues 226 and 228 (31) , two residues that lie on the edge of the RBD. Why the murine immune response to H2 HA is so focused on the conserved RBD is not clear (16) . However, human monoclonal antibodies against H2 HA also seem to be focused on this very same pocket (16, 17 
CROSS-REACTIVITY OF GLOBULAR HEAD HA ANTIBODIES
Since the HA stem is conserved within group 1 HA viruses (which includes several subtypes that have infected humans: H1, H2, H5) and group 2 HA viruses (which includes additional subtypes that have infected humans: H3, H7), respectively, some stem antibodies can neutralize multiple strains across subtypes. However, because of hypervariability of loops surrounding the RBD, the cross-reactive potential of globular head antibodies is generally thought to be more limited. Cross-reactive antibodies to the globular head HA can bind outside of the conserved RBD. Some particularly well-studied examples are the human pandemic H1N1 mAbs 2D1 (2, 20, 32, 33) ( (20) . It is generally believed that glycosylation at these sites shields HA from neutralization (20, 35) . However, we were able to clone a panel of neutralizing antibodies that bound the Sa site based on escape mutations of the Sa site residue K166, but that were still able to neutralize A/USSR/1977 H1N1 despite the presence of said glycosylation sites (14) . We presently do not understand the structural basis for the fact that glycosylation within the Sa site does not always confer escape from Sa-specific mAbs. Unexpectedly, this panel of independent antibody clones that was derived of the V H 3-7/J H 6 germ line heavy chain genes converged toward similar mutations (14) . Interestingly, even essentially unmutated states of those antibodies were found in the peripheral blood (14) . Persistent lowaffinity memory populations may aid in the immunologic response toward a related HA that the individual subsequently encounters (8, 14, 36) .
ANTIBODIES THAT TARGET RESIDUES THAT MEDIATE RECEPTOR SPECIFICITY
We cloned both mAbs 1F1 and 1I20 from one survivor of the 1918 H1N1 pandemic (33) . The heavy chains of those antibodies are genetically related, but clonally independent. MAb 1I20 is strain specific, but mAb 1F1 is able to neutralize select H1N1 strains across the 20th century (33), including 1943, 1947, and 1977 viruses, but not the pandemic 2009 H1N1 virus (20) . These antibodies selected for escape mutations in position P186 adjacent to the Sb antigenic site (33) . The cocrystal structure of 1F1 in complex with 1918 HA shows that 1F1 does indeed make multiple contacts within the 190-helix of the Sb antigenic site, but also touches on the Ca 2 antigenic site, and reaches into the RBD (23) ( Table 2 ). This finding supports our hypothesis that most human antibodies contact multiple conventional antigenic sites, although the number of influenza antibody cocrystal structures is too limited so far to state that this is a universal characteristic of human neutralizing antibodies to HA head domain. In addition to those conventionally defined antigenic sites, 1F1 contacts several HA residues that typically interact with the sialoglycan receptor, including 135, 153, 183, 190, 194, 222, and 225 (23) . Residues D190 and D225 mediate H1 HA receptor specificity (31, 37, 38, 39, 40, 41, 42) . Reverting these residues to D190E and D225G of avian H1N1 viruses significantly reduces binding for both 1F1 and 1I20 (23) . While it is not surprising that two antibodies with similar genetic backgrounds recognize the same epitope (as was seen also for the V H 3-7/J H 6 germ line antibodies mentioned above [14] ), we were surprised to see that the epitope of 1F1 on H1 HA is similar to the murine mAb HC63 epitope on H3 HA (28, 43) , despite a rotation of the heavy chains by 20°, resulting in completely different interactions for the light chains of 1F1 and HC63. There may be only a limited number of preferred antibody-binding modes even across subtypes (23) . HC63 can not only inhibit receptor binding, but also inhibits the pH-induced conformational change that happens upon receptor binding, because HC63 binds multiple HA monomers (28, 43) ; 1F1 Fab does not share these features (23) . Table 2 ). The CH65 CDR-H3 inserts into the RBD on HA1 where it mimics the physiologic receptor, sialic acid (15) . CH65-resistant H1N1 strains seemed to have an insertion in position 133A of the HA, either an arginine or a lysine (15), but Schmidt et al. later found exceptions to this assumption (44) . Similarly, we reported the H1N1 cross-reactive mAb 5J8 that neutralizes a broad range of H1N1 strains of the 20th century and the pandemic strains of H1N1, a spectrum of activity that seemed complementary to the mAb CH65 (13) . Indeed, mAb 5J8-resistant H1N1 strains did not have an insertion in position 133A of the HA (13) . Also, a cocrystal structure of 5J8 in complex with the globular HA1 head domain of A/California/07/ 2009 HA revealed that 5J8 also uses receptor mimicry, but both antibodies have distinct footprints and different angles of approach (45) . Antibodies such as 5J8 may have also contributed to the preexisting immunity toward the pandemic 2009 virus (13), although we speculate that such antibodies were less frequent than Sa site-specific antibodies such as 2D1 (14, 20, 32, 33) . MAb 5J8 elicited escape mutations in position 133A, 137, and 222, none of which is part of a conventionally defined H1N1 antigenic site and all of which are relatively well-conserved (13) . It seems likely that H1N1 cannot easily change such residues without the loss of replicative capacity (13) .
ANTIBODIES THAT MIMIC SIALIC ACID, THE INFLUENZA RECEPTOR
The human H2N2 mAbs 8M2, 2G1, and 8F8 are also directed against the RBD (16, 17) . 8M2 and 2G1 are encoded by the V H 1-69 germ line gene that was conventionally thought of as being stem specific, but it is also ideally suited for recognition of another structurally conserved influenza hydrophobic pocket, the HA RBD (17) . Even though 8M2 and 2G1 were cloned from two different individuals, they both insert germ line Phe54 of CDR-H2 into the RBD, and thus provide further evidence of sequence convergence across antibodies (14) . In the H2-antibody complexes, the aromatic rings of Phe54 are situated for optimal π-π interaction with the universally conserved HA Trp153 and are surrounded by further highly conserved influenza A residues (17) . MAb 8F8, a V H 3-33-encoded antibody, interacts with HA Trp153 through the insertion of aromatic residue Tyr100 of CDR-H3. Escape is mediated through residues that are on the edge of the RBD (16) .
MAb 2G1 showed hemagglutination-inhibition (HAI) activity against H2N2 viruses, but also against the pandemic H3N2 virus from 1968 (16) . The human V H 1-69 encoded mAb F045-092 that was derived of phage display technology has been reported to cross-neutralize select strains from an even broader spectrum of influenza subtypes (H1, H2, H3, and H13) (46) . S139/1 was the first head-specific mAb to be described to neutralize select strains from different influenza subtypes (H1, H2, H3, and H13; Table 2 ) (47). The crystal structure of the S139/1 Fab in complex with the HA from the A/ Victoria/3/1975 (H3N2) virus reveals that the mAb targets residues within the RBD and contacts antigenic sites A, B, and D (48) . Although S139/1 Fab is sufficient for neutralization of most H3N2 viruses, it depends on the avidity mediated by the bivalent IgG for its heterosubtypic neutralization (48) . The extension of breadth through avidity is also a feature for other mAbs that target the RBD (45, 49) .
The footprint of an antibody on HA is larger than the RBD, so an antibody will have to bind to at least some hypervariable residues and can compensate for this fact by avoiding high-affinity interactions dependent on ASMscience.org/MicrobiolSpectrumthese positions (48) . An antibody features three hypervariable loops each on the heavy and light chain, but not all of those loops typically participate in the antigenantibody interaction. An antibody with a very long CDR-H3 can minimize its footprint on the antigen (49). Ekiert et al. reported such an antibody, designated mAb C05; it binds and/or neutralizes selected strains from H1, H2, H3, H9, and H12 subtypes ( Table 2) . Apart from CDR-H3, only CDR-H1 makes additional minor interactions with HA, and only 550 Å 2 of surface area is buried on the HA by C05 (49) . As with other RBD antibodies, insertions at position 133A seem to abrogate binding (49) . And unlike other RBD antibodies, C05 interaction with the RBD differs considerably from sialic acid binding to HA (49) . Insertions and deletions at other positions explain why other HA subtypes are not bound and/or neutralized (49) .
CONCLUSIONS AND AREAS FOR FUTURE STUDIES
The antibodies described here have important potential diagnostic and therapeutic applications. Antibodies such as 1F1 or 8M2 that recognize viruses with human-receptor specificity only, but not avian-receptor specificity, could be used to screen for viruses with supposedly greater human infectivity. A collection of broadly neutralizing monoclonal antibodies can be used for comparative studies, for example, to facilitate the development of universal vaccines directed against the RBD. Passive administration of such antibodies to humans could provide protective immunity, for example, for immunocompromised individuals that would not be expected to mount a protective immune response after active immunization. Antibodies against respiratory-droplet-transmissible avian H5N1 viruses could be used as postexposure prophylaxis (50) . Computational designs of proteins against the stem region of HA have yielded novel proteins inhibitors (51) that can be further optimized by creating comprehensive sequencefunction maps obtained by deep sequencing (52) . The wealth of cross-reactive antibodies against the RBD could serve as templates to design novel influenza therapeutics directed against the RBD of HA by using similar approaches. Because only few residues are universally conserved across all HAs, and such residues will likely not be the only contact residues of novel therapeutics, escape mutations will invariably occur. Based on existing structures and naturally occurring variability in those residues, it seems possible to rationally predict such escape mutations (49) . One single protein or small molecule might not be sufficient to neutralize all influenza strains. It might be possible to develop multiple different inhibitors that could be tailored toward specific strains or used in conjunction with other inhibitors (including neuraminidase inhibitors) as an inhibitor cocktail.
The challenge remains how to elicit reliably broadly cross-neutralizing human mAb through vaccination. Studies suggest that individuals may have a greater chance of mounting a robust cross-neutralizing antibody response if primed with DNA vaccines (53) or immunized with adjuvants (54) . The conserved stem epitopes seem to be predominantly encoded by the V H 1-69 germ line gene. Given that there is variability in V H 1-69 alleles and the number of V H 1-69 alleles a person carries, some individuals may mount a more robust immune response toward the stem than others. Even though we (16, 17) and others (46) have shown that the V H 1-69 gene element plays an important role for antibodies against the RBD as well, the still limited number of globular head antibodies suggests a more diverse genetic heritage of RBD mAbs. Although antibodies such as C05 with its 24-amino-acid CDR-H3 and 5-amino-acid insertion in CDR-H1 stand out (49), unlike HIV antibodies, most cross-reactive human influenza antibodies analyzed so far do not seem to need unusual structural features or an extraordinarily high number of somatic mutations to achieve cross-reactivity. This observation suggests that it may be easier to induce influenza cross-reactive antibodies than cross-reactive HIV antibodies. It has been proposed to design immunogens to guide precursors of mature B cells in multiple steps toward a desired response (55) . We believe that H2 influenza may be a key for the design of a universal vaccine against influenza since its RBD seems to be particularly immunogenic. The molecular or structural basis for this phenomenon is not immediately apparent from structures of H2 HA by itself or in complex with antibodies (17) , although the mechanism may be related to the paucity of glycosylation sites on the globular head of H2 HA. Glycosylation can modulate the ability of HA to induce cross-reactive antibodies (56) . Increasing the immunogenicity of the RBD in influenza vaccines by modifying select residues of the HA globular head would be major step toward developing an additional component of a universal vaccine.
